In the phase 1/2a trail AKCEA-APOCIII-LRx (NCT02900027), olezarsen treatments led to a significant reduction of APOC3 and triglycerides levels and, most importantly, no case of thrombocytopenia was reported132. This evidence concerns the gene APOC3 and Thrombocytopenia.